

**Hem-Onc Weekly Series (8/5/2023-8/4/2024)**

**Hem-Onc Weekly Series - 10/20/2023**

October 20, 2023 8:00 AM

Other

**Description**

A weekly meeting on Friday at 8:00 am to discuss retrospective cancer cases and relative journal articles to improve practice.

**Learning Objectives**

1 Diagnose, stage, and prognosticate specific cancers.

2 Apply evidence-based treatment paradigms.

**Accreditation**

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the Quillen College of Medicine, East Tennessee State University. The Quillen College of Medicine, East Tennessee State University is accredited by the ACCME to provide continuing medical education for physicians.

**Credit Designation**

**CME Credit:** The East Tennessee State University, Quillen College of Medicine designates this activity for a maximum of 1.00 *AMA PRA Category 1 Credit(s)*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Non-Physician Credit:** Quillen College of Medicine, East Tennessee State University designates this activity for a maximum of 1.00 participation hours.

Should you need special accommodation to fully participate in the program,

please contact the Office of CME at (423) 439-8027.

Please allow sufficient time to arrange the accommodation.

**Faculty & Planners**

|  |  |  |
| --- | --- | --- |
| **Name of individual** | **Individual's role in activity** | **Nature of Relationship(s) / Name of Ineligible Company(s)** |
| Melissa S Hood, MPH | Other Planning Committee Member | Nothing to disclose - 07/13/2023 |
| DEVAPIRAN JAISHANKAR, MD, Professor of Medicine, Division Chief & Program Director Medical Oncology ETSU | Course Director | Nothing to disclose - 06/23/2023 |
| Kanishka Chakraborty, MD | Co-Director |  |
| Arjun Natarajan, MBBS | Activity Coordinator | Nothing to disclose - 05/23/2023 |

**Commercial Support**

This activity has been developed without commercial support.